Navigation Links
New international Ph.D. program on 'Dynamics of Gene Regulation, Epigenetics and DNA Damage Response'
Date:12/21/2011

The Institute of Molecular Biology (IMB) can establish a new International PhD Program in the Life Sciences with the support of the Boehringer Ingelheim Foundation. The program will allow innovative research at the highest international level. In addition to the education of talented young scientists, this initiative improves the integration of institutions in Mainz that conduct research within the field of molecular biology. "The new initiative will help to create synergies between the participating groups. The program will also increase the visibility and international attractiveness of life science research here in Mainz," says Professor Dr. Georg Krausch, President of Johannes Gutenberg University Mainz.

One of the program's key features is the education of doctoral students. "We not only want to attract the best international talents to Mainz, but we also want to offer them opportunities that most institutions cannot offer," states Professor Dr. Christof Niehrs, Founding Director of IMB. Moreover, "we offer our young scientists opportunities to address cutting-edge scientific questions and to work with first-class resources while receiving advanced training." The training program comprises a broad range of lectures and practical courses and is tailored to the specific needs of PhD students. Besides training in up-to-date methods and knowledge, students will be trained in soft-skills such as project management, communication skills, and grant writing to prepare them for a successful career after having finished their doctoral thesis.

The organizers of the program hope this concept will lead to exciting research results and, when combined with very high educational standards, will create the next generation of leading scientists. "This program will set new standards in modern molecular research. Our most sincere thanks go to the Boehringer Ingelheim Foundation. Their further commitment to IMB allows us to attract young and talented scientists to Mainz and also guarantees that our students receive the best possible education," says Gtz Scholz, Chancellor of Johannes Gutenberg University Mainz and Managing Director of IMB.

Research within the program focuses on three cutting-edge areas: Dynamics of Gene Regulation, Epigenetics, and DNA Damage Response. These emerging fields of modern biomedical research are of great significance for basic biological processes and are also linked to diseases such as cancer. For example, the dynamics of gene regulation and epigenetics play an essential role during embryonic development, the adaption of organisms to its environment as well as during ageing, and are of high importance in many diseases. Moreover, the program offers research projects on stem cell biology, which forms the basis for regenerative medicine. The third research focus centers on DNA Damage Response. DNA repair is a key mechanism that protects cells from damage and keeps us healthy. Defects in the DNA repair machinery cause a number of diseases, including cancer.


'/>"/>
Contact: Dr. Ralf Dahm
press@imb-mainz.de
49-613-139-21450
Johannes Gutenberg Universitaet Mainz
Source:Eurekalert

Related biology news :

1. BIO-key(R) International To Exhibit at Oracle OpenWorld
2. Sentara begins international trial -- open at only 24 US locations
3. Perinatal Days and International Stillbirth Conference -- Nov.5-7
4. AVS 55th International Symposium & Exhibition, Oct. 19-24
5. Minnesota ecology professor wins international award for biodiversity and biofuels research
6. International Council for Science launches major research program on natural disasters
7. Innovations in Pediatric Medicine International Conference brings together pediatrics experts
8. International Journal of Social Robotics debuts at Springer
9. Conservation International gets support from Dreamworks Animation to protect giant pandas
10. AACR to host Seventh Annual International Conference on Frontiers in Cancer Prevention Research
11. Engineer to present leak-proof method for carbon dioxide storage at international conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... (TDR) procedures can be safely completed in an ambulatory surgery center (ASC) with ... (ACDF) procedures and previous two-year TDR studies. , Jake Lubinski, president of ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
Breaking Biology Technology: